Press Releases

Investors

Press Releases

 
Press Releases
  Date Title and Summary View
Sep 7, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in the multiple ascending dose (MAD) portion of its ongoing Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic ...
Sep 6, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 2 clinical study of ARC-AAT, an investigational RNAi-based medicine for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). The study is designed to evaluat...
Sep 1, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events. The 23rd Annual NewsMakers in the Biotech Industry - New York, September 9, 2016 September 9, 10:00...
Aug 12, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors. Gross ...
Aug 9, 2016
Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 third quarter ended June 30, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss ...
Aug 9, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million. The offering was priced at $5.90 per share. Cantor Fitzgerald & Co. acted as sole placement ag...
Aug 1, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, August 9, 2016, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2016 third quarter ended June 30, 2016. Investors may access a live audio w...
Jul 6, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.D., will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 13, 2016 at 10:45 a.m. EDT in New York. In...
Jun 9, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. The study is designed to evaluate the safety, ...
Jun 3, 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.D., will present at the Jefferies 2016 Healthcare Conference on June 10, 2016 at 10:30 a.m. EDT. Investors may access live and archived versions of the audi...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase